177 related articles for article (PubMed ID: 15078402)
1. Nitrous oxide sedation reduces discomfort caused by atrial defibrillation shocks.
Ujhelyi M; Hoyt RH; Burns K; Fishman RS; Musley S; Silverman MH
Pacing Clin Electrophysiol; 2004 Apr; 27(4):485-91. PubMed ID: 15078402
[TBL] [Abstract][Full Text] [Related]
2. A randomized clinical trial of continuous flow nitrous oxide and nalbuphine infusion for sedation of patients during radiofrequency atrial flutter ablation.
Laurent G; Bertaux G; Martel A; Fraison M; Fromentin S; Gonzalez S; Pierre FS; Wolf JE
Pacing Clin Electrophysiol; 2006 Apr; 29(4):351-7. PubMed ID: 16650261
[TBL] [Abstract][Full Text] [Related]
3. Improving the acceptability of the atrial defibrillator: patient-activated cardioversion versus automatic night cardioversion with and without sedation (ADSAS 2).
Boodhoo L; Mitchell A; Ujhelyi M; Sulke N
Pacing Clin Electrophysiol; 2004 Jul; 27(7):910-7. PubMed ID: 15271009
[TBL] [Abstract][Full Text] [Related]
4. Decreasing pain and anxiety associated with patient-activated atrial shock: a placebo-controlled study of adjunctive sedation with oral triazolam.
Fabian TJ; Schwartzman DS; Ujhelyi MR; Corey SE; Bigos KL; Pollock BG; Kroboth PD
J Cardiovasc Electrophysiol; 2006 Apr; 17(4):391-5. PubMed ID: 16643361
[TBL] [Abstract][Full Text] [Related]
5. Do patients accept implantable atrial defibrillation therapy? Results from the Patient Atrial Shock Survey of Acceptance and Tolerance (PASSAT) Study.
Burns JL; Sears SF; Sotile R; Schwartzman DS; Hoyt RH; Alvarez LG; Ujhelyi MR
J Cardiovasc Electrophysiol; 2004 Mar; 15(3):286-91. PubMed ID: 15030417
[TBL] [Abstract][Full Text] [Related]
6. Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of life.
Newman DM; Dorian P; Paquette M; Sulke N; Gold MR; Schwartzman DS; Schaaf K; Wood K; Johnson L;
Am Heart J; 2003 May; 145(5):841-6. PubMed ID: 12766741
[TBL] [Abstract][Full Text] [Related]
7. Psychophysiologic and affective parameters associated with pain intensity of cardiac cardioverter defibrillator shock discharges.
Baumert J; Schmitt C; Ladwig KH
Psychosom Med; 2006; 68(4):591-7. PubMed ID: 16868269
[TBL] [Abstract][Full Text] [Related]
8. Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure.
Singh SN; Poole J; Anderson J; Hellkamp AS; Karasik P; Mark DB; Lee KL; Bardy GH;
Am Heart J; 2006 Nov; 152(5):974.e7-11. PubMed ID: 17070171
[TBL] [Abstract][Full Text] [Related]
9. Utility of adjunctive single oral bolus propafenone therapy in patients with atrial defibrillators.
Schwartzman D; Harvey MN; Hoyt RH; Koehler JL; Ujhelyi MR; Euler DE
Europace; 2006 Mar; 8(3):211-5. PubMed ID: 16627442
[TBL] [Abstract][Full Text] [Related]
10. Concerns about the implantable cardioverter defibrillator: a determinant of anxiety and depressive symptoms independent of experienced shocks.
Pedersen SS; van Domburg RT; Theuns DA; Jordaens L; Erdman RA
Am Heart J; 2005 Apr; 149(4):664-9. PubMed ID: 15990750
[TBL] [Abstract][Full Text] [Related]
11. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.
Daubert JP; Zareba W; Cannom DS; McNitt S; Rosero SZ; Wang P; Schuger C; Steinberg JS; Higgins SL; Wilber DJ; Klein H; Andrews ML; Hall WJ; Moss AJ;
J Am Coll Cardiol; 2008 Apr; 51(14):1357-65. PubMed ID: 18387436
[TBL] [Abstract][Full Text] [Related]
12. External cardioversion of atrial fibrillation in patients with implanted pacemaker or cardioverter-defibrillator systems: a randomized comparison of monophasic and biphasic shock energy application.
Manegold JC; Israel CW; Ehrlich JR; Duray G; Pajitnev D; Wegener FT; Hohnloser SH
Eur Heart J; 2007 Jul; 28(14):1731-8. PubMed ID: 17569681
[TBL] [Abstract][Full Text] [Related]
13. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
[TBL] [Abstract][Full Text] [Related]
14. Inhaled nitrous oxide versus placebo as an analgesic and anxiolytic adjunct to peripheral intravenous cannulation.
Gerhardt RT; King KM; Wiegert RS
Am J Emerg Med; 2001 Oct; 19(6):492-4. PubMed ID: 11593469
[TBL] [Abstract][Full Text] [Related]
15. Intracardiac atrial defibrillation.
Dosdall DJ; Ideker RE
Heart Rhythm; 2007 Mar; 4(3 Suppl):S51-6. PubMed ID: 17336885
[TBL] [Abstract][Full Text] [Related]
16. Nitrous oxide/oxygen inhalation provides effective analgesia during the administration of tumescent local anaesthesia for endovenous laser ablation.
Meier TO; Jacomella V; Clemens RK; Amann-Vesti B
Vasa; 2015 Nov; 44(6):473-8. PubMed ID: 26515225
[TBL] [Abstract][Full Text] [Related]
17. Improving the acceptability of the atrial defibrillator for the treatment of persistent atrial fibrillation: the atrial defibrillator sedation assessment study (ADSAS).
Mitchell AR; Spurrell PA; Gerritse BE; Sulke N
Int J Cardiol; 2004 Aug; 96(2):141-5. PubMed ID: 15262026
[TBL] [Abstract][Full Text] [Related]
18. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
[TBL] [Abstract][Full Text] [Related]
19. Patient-assisted computerized education for recipients of implantable cardioverter defibrillators: a randomized controlled trial of the PACER program.
Kuhl EA; Sears SF; Vazquez LD; Conti JB
J Cardiovasc Nurs; 2009; 24(3):225-31. PubMed ID: 19390340
[TBL] [Abstract][Full Text] [Related]
20. Reduction of ventricular tachyarrhythmia by treatment of atrial fibrillation in ICD patients with dual-chamber implantable cardioverter/defibrillators capable of atrial therapy delivery: the REVERT-AF Study.
Gradaus R; Seidl K; Korte T; Himmrich E; Wieneke H; Schuchert A; Bauer W; Gerss J; Wollmann CG; Borggrefe M; Böcker D
Europace; 2007 Jul; 9(7):534-9. PubMed ID: 17440005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
